高级检索
当前位置: 首页 > 详情页

CD2+ T-helper 17-like cells differentiated from a CD133+ subpopulation of non-small cell lung carcinoma cells promote the growth of lung carcinoma.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Institute of Basic Medicine, Hebei Medical University, Shijiazhuang, China [2]Research Unit of Digestive Tract Microecosystem Pharmacology and Toxicology, Chinese Academy of Medical Sciences, Shijiazhuang, China [3]College of Forensic Medicine, Hebei Key Laboratory of Forensic Medicine, Collaborative Innovation Center of Forensic Medical Molecular Identification, Hebei Medical University, Shijiazhuang, China [4]Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
出处:
ISSN:

关键词: Non-small cell lung carcinoma (NSCLC) cancer stem cells (CSCs) differentiation tumor microenvironment (TME) Th17

摘要:
Cancer stem cells (CSCs) give rise to a diverse variety of differentiated cells, which comprise the bulk of the tumor microenvironment (TME). However, the exact multi-directional differentiation potential of CSCs has not been fully clarified. This study was designed to explore whether CSCs differentiate into cellular components of the TME to promote the growth of lung carcinoma. The present of CD133+, CD2+, and CD133+CD2+ cells in both clinical lung adenocarcinoma tissue and non-small cell lung carcinoma (NSCLC) cell lines were monitored using polymerase chain reaction (PCR) Array, flow cytometry (FCM), quantitative real-time PCR (qRT-PCR) and immunohistofluorescence (IF). Stem-like properties of CD133+ cells and CD2+ cells were detected by sphere formation assay, IF, and western blot. Colony formation and xenograft tumors experiments were performed to assess the malignant behaviors of CD2+ cells. The differentiation of CD133+ cells to CD2+ Th17-like cells was observed by FCM. The interleukin (IL)-2/phosphorylated signal transducer and activator of transcription protein 5 (pSTAT5)/retinoic acid receptor-related orphan receptor gamma t (RORγt) signaling pathway was evaluated by western blot and FCM. We found that CD133+ cells within both clinical lung adenocarcinoma tissue and NSCLC cell lines included a subset of CD2-expressing cells, which were correlated with the grade of malignancy (r=0.7835, P<0.01) and exhibited stem-like properties. Then, we determined the tumorigenic effects of CD2 on the growth of transplanted Lewis lung carcinoma cells (LLC1) in C57/BL6 mice. The results indicated that CD2+ cells were effective in promoting tumor growth in vivo (P<0.01). Furthermore, we obtained direct evidence of an ability of CD133+ cells to transform to T-helper 17-like cells via an intermediate CD133+CD2+ progenitor cell that is able to secrete IL-17A and IL-23. Furthermore, we found that IL-2 can inhibit the production of T-helper 17-like cells (P<0.001) by modulating the activation of STAT5 signaling pathways to downregulate the expression of RORγt (P<0.001). Our data demonstrates that Th17-like cells generated from CSCs support cancer progression. These findings enrich the definition of multidirectional differentiation potential of CSCs and improve the understanding of the role of CSCs in cancer progression, which aids the improvement and creation of therapies. 2021 Annals of Translational Medicine. All rights reserved.

基金:

基金编号: GCC2014004 2019-12M-5055 H2020206579 20327125D

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 3 区 医学:研究与实验 3 区 肿瘤学
最新[2025]版:
JCR分区:
出版当年[2021]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q3 ONCOLOGY
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版]

第一作者:
第一作者机构: [1]Institute of Basic Medicine, Hebei Medical University, Shijiazhuang, China [2]Research Unit of Digestive Tract Microecosystem Pharmacology and Toxicology, Chinese Academy of Medical Sciences, Shijiazhuang, China
共同第一作者:
通讯作者:
通讯机构: [1]Institute of Basic Medicine, Hebei Medical University, Shijiazhuang, China [2]Research Unit of Digestive Tract Microecosystem Pharmacology and Toxicology, Chinese Academy of Medical Sciences, Shijiazhuang, China [3]College of Forensic Medicine, Hebei Key Laboratory of Forensic Medicine, Collaborative Innovation Center of Forensic Medical Molecular Identification, Hebei Medical University, Shijiazhuang, China [*1]Institute of basic Medicine, Hebei Medical University, No. 361 Zhongshan East Road, Shijiazhuang 050017, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号